Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 5/20 | 0.47 |
| ▸ | RARG | P13631 | 5/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | RARA | P10276 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 3/20 | 0.44 |
| ▸ | RXRB | P28702 | 3/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14825526 | 0.87 | LMNA (0.47) | LMNAMAPK1HTTRAB9ARARB | |
| SCHEMBL31401262 | 0.87 | LMNA (0.47) | LMNAMAPK1HTTRAB9ARARB | |
| SCHEMBL26090159 | 0.87 | LMNA (0.47) | LMNAMAPK1HTTRAB9ARARB | |
| SCHEMBL11977452 | 0.85 | LMNA (0.53) | LMNAMAPK1HTTRAB9ARARB | |
| SCHEMBL11346841 | 0.83 | AR (0.46) | TAS1R3TAS1R1TAS1R2KDM4ECES2 | |
| SCHEMBL78878 | 0.82 | TAS1R3 (0.54) | LMNAMAPK1HTTRAB9ARXRA | |
| SCHEMBL31438988 | 0.82 | TAS1R3 (0.54) | LMNAMAPK1HTTRAB9ARXRA | |
| SCHEMBL13653068 | 0.82 | RARB (0.51) | RARBRARGNR1H4RARARXRA | |
| SCHEMBL31401512 | 0.81 | LMNA (0.42) | LMNAMAPK1HTTRAB9ARARB | |
| SCHEMBL4207235 | 0.81 | LMNA (0.42) | LMNAMAPK1HTTRAB9ARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186587-B2 | Compound as ACC inhibitor and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200165265-A1 | COMPOUND AS ACC INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019118571-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-09-01 | — | — | US | disclosed |
| US-9382216-B2 | Substituted morpholines as modulators for the calcium sensing receptor | LUPIN LIMITED (IN) | 2016-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | LMNA 3944/4885MAPK1 3226/4885HTT 3860/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | LMNA 3944/4885MAPK1 3226/4885HTT 3860/4885 |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, GPBAR1 | LMNA 4269/4885MAPK1 2991/4885HTT 3377/4885 |
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | CASR, RYR1, RYR2 | LMNA 1391/4885MAPK1 1066/4885HTT 2747/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | LMNA 3944/4885MAPK1 3226/4885HTT 3860/4885 |
| US-20200165265-A1 | COMPOUND AS ACC INHIBITOR AND USE THEREOF | ACACA, ACACB, ACAT2 | LMNA 2070/4885MAPK1 1398/4885HTT 3815/4885 |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | SLC10A1, NR1H4, GPBAR1 | LMNA 4269/4885MAPK1 2991/4885HTT 3377/4885 |
| US-11186587-B2 | Compound as ACC inhibitor and use thereof | ACACA, ACACB, ACAT2 | LMNA 2070/4885MAPK1 1398/4885HTT 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.